Semaglutide dosage, planned by the book.
Standard titration schedule plus expected weight-loss ranges from the STEP trial. Educational only.
Educational only — not a prescription. Semaglutide is a prescription medication (Wegovy, Ozempic). Dosage, titration pace, and suitability must be decided with a licensed clinician. These estimates come from published STEP trial averages and don’t apply to everyone.
Semaglutide titration & weight-loss estimator
Current BMI
29.4kg/m²
Goal BMI
25.5kg/m²
Time to goal ≈
37 weeks
Trial-average pace.
| Weeks | Weekly dose | Avg weight | Cumulative loss |
|---|---|---|---|
| 1–4 | 0.25 mg | 88.7 kg | 1–2% |
| 5–8 | 0.5 mg | 87.8 kg | 2–3% |
| 9–12 | 1 mg | 84.6 kg | 5–7% |
| 13–16 | 1.7 mg | 80.1 kg | 10–12% |
| 17+ | 2.4 mg | 75.6 kg | 15–17% |
Good to know
What is semaglutide?+
A GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic), approved at higher doses for chronic weight management (Wegovy). It works by slowing gastric emptying and reducing appetite.
Where do these weight-loss numbers come from?+
The STEP 1 trial (Wilding et al., NEJM 2021) reported mean ~15% body-weight loss at 68 weeks on 2.4 mg/week semaglutide. Earlier-tier percentages come from the same study's titration timeline.
Who shouldn't take semaglutide?+
People with a personal or family history of medullary thyroid carcinoma, MEN2, pregnancy, or severe GI disease. Always screen with a licensed clinician — never start or titrate without medical oversight.
